Abstract
A novel series of 2-aryl-1, 2, 4 – triazolo [1, 5-a] pyridine derivatives have been synthesized and evaluated for their cytotoxic activities in vitro against Human ovarian cancer cell line (HO-8910) and Human liver cancer cell line (Bel 7402). Most compounds showed high or mediate activity against the cancer cell lines when compared with Cisplatin. Two of them were tested the apoptosis on Bel 7402.
Keywords: Synthesis, antitumor activity, 2- aryl-1, 2, 4, –, triazolo [1, 5-a] pyridine
Medicinal Chemistry
Title: Synthesis and Antitumor Activity of 2-Aryl-1, 2, 4-Triazolo[1, 5-a] Pyridine Derivatives
Volume: 6 Issue: 2
Author(s): Xuefen Tao and Yongzhou Hu
Affiliation:
Keywords: Synthesis, antitumor activity, 2- aryl-1, 2, 4, –, triazolo [1, 5-a] pyridine
Abstract: A novel series of 2-aryl-1, 2, 4 – triazolo [1, 5-a] pyridine derivatives have been synthesized and evaluated for their cytotoxic activities in vitro against Human ovarian cancer cell line (HO-8910) and Human liver cancer cell line (Bel 7402). Most compounds showed high or mediate activity against the cancer cell lines when compared with Cisplatin. Two of them were tested the apoptosis on Bel 7402.
Export Options
About this article
Cite this article as:
Tao Xuefen and Hu Yongzhou, Synthesis and Antitumor Activity of 2-Aryl-1, 2, 4-Triazolo[1, 5-a] Pyridine Derivatives, Medicinal Chemistry 2010; 6 (2) . https://dx.doi.org/10.2174/157340610791321505
DOI https://dx.doi.org/10.2174/157340610791321505 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Assembly of Quinoline, Triazole and Oxime Ether in a Single Molecular Entity: A Greener and One-pot Synthesis of Novel Oximes as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Quantitative Proteomics for Cancer Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design TGFb and its Smad Connection to Cancer
Current Genomics Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Metabolic Alterations in Renal and Prostate Cancer
Current Drug Metabolism Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment
Current Topics in Medicinal Chemistry Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
Current Chemical Biology Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Myokines in Myogenesis and Health
Recent Patents on Biotechnology Computed Tomography Contribution to Virtual Preoperative Liver Resection Planning
Recent Patents on Medical Imaging Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry